Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

 
• By Joseph Haas

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Cholesterol plaque in artery
Nexletol's unique mechanism of action inhibits the synthesis of cholesterol in the liver

More from New Products

More from Scrip